Bedeutung der Dosimetrie bei der Therapie aus Sicht der Medizinischen Physik

Zusammenfassung

Der Beitrag der Medizinischen Physik zur Dosimetrie bei der Radionuklidtherapie umfasst die Qualitätssicherung der eingesetzten Geräte, die Erstellung von Protokollen zur prä- und peritherapeutischen Dosimetrie, die Planung der Therapien bzw. deren Verifikation sowie eigenständige Forschung zur Methodenentwicklung in der Dosimetrie. Eine nach dem Stand von Wissenschaft und Technik durchgeführte Dosimetrie ist gerade bei Therapien, die nicht als Standardtherapie anzusehen sind, von hoher Bedeutung. Zum einen ermöglicht die Dosimetrie zur Therapieplanung und –verifikation die Optimierung des Strahlenschutzes für die Patienten. Andererseits ist die Dosimetrie von großer Bedeutung für die Planung und praktische Umsetzung neuer Therapieverfahren sowie für die Gewinnung und Berücksichtigung strahlenbiologischer Erkenntnisse. In jedem Fall leistet die Medizinische Physik einen unverzichtbaren Beitrag zur Optimierung der Behandlung nuklearmedizinischer Patienten mit radioaktiven Substanzen.

Abstract

The contribution of medical physics to dosimetry in radionuclide therapy includes the quality assurance of the devices used, the preparation of protocols for pre- and peritherapeutic dosimetry, the planning of therapies and their verification, as well as independent research on method development in dosimetry. Dosimetry carried out according to the state of the art in science and technology is of great importance, especially for non-standard therapies. Dosimetry for treatment planning and verification enables the optimization of radiation protection for patients. Furthermore, dosimetry is highly important for planning and practical implementation of new therapy procedures as well as for acquiring and considering radiobiological findings. In any case, medical physics is indispensable to optimizing the treatment of nuclear medicine patients with radiopharmaceuticals.

Schlüsselwörter

Medizinische Physik - Radionuklidtherapie - Therapieplanung - Dosimetrie

Keywords

Medical Physics - Radionuclide Therapy - Treatment Planning - Dosimetry

• Literatur

• 1 Lawhn-Heath C, Hope TA, Martinez J. et al. Dosimetry in radionuclide therapy: the clinical role of measuring radiation dose. The lancet oncology 2022; 23: e75-e87
• 2 Poeppel TD, Handkiewicz-Junak D, Andreeff M. et al. EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging 2018; 45: 824-845
• 3 Bodei L, Mueller-Brand J, Baum RP. et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2013; 40: 800-16
• 4 Sartor O, de Bono J, Chi KN. et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med 2021; 385: 1091-1103
• 5 Kolstad A, Illidge T, Bolstad N. et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv 2020; 4: 4091-4101
• 6 Strigari L, Konijnenberg M, Chiesa C. et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging 2014; 41: 1976-1988
• 7 Konijnenberg M, Herrmann K, Kobe C. et al. EANM position paper on article 56 of the Council Directive 2013/59/Euratom (basic safety standards) for nuclear medicine therapy. Eur J Nucl Med Mol Imaging 2021; 48: 67-72
• 8 Garin E, Tselikas L, Guiu B. et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6: 17-29
• 9 Flux G, Bardies M, Monsieurs M. et al. The impact of PET and SPECT on dosimetry for targeted radionuclide therapy. Z Med Phys 2006; 16: 47-59
• 10 Taprogge J, Leek F, Schurrat T. et al. Setting up a quantitative SPECT imaging network for a European multi-centre dosimetry study of radioiodine treatment for thyroid cancer as part of the MEDIRAD project. EJNMMI physics 2020; 7
• 11 Tran-Gia J, Denis-Bacelar AM, Ferreira KM. et al. A multicentre and multi-national evaluation of the accuracy of quantitative Lu-177 SPECT/CT imaging performed within the MRTDosimetry project. EJNMMI physics 2021; 8: 55
• 12 Gear JI, Cox MG, Gustafsson J. et al. EANM practical guidance on uncertainty analysis for molecular radiotherapy absorbed dose calculations. Eur J Nucl Med Mol Imaging 2018; 45: 2456-2474
• 13 Council of the European Union. COUNCIL DIRECTIVE 2013/59/EURATOM of 5 December 2013 laying down basic safety standards for protection against the dangers arising from exposure to ionising radiation, and repealing Directives 89/618/Euratom, 90/641/Euratom, 96/29/Euratom, 97/43/Euratom and 2003/122/Euratom. Official Journal of the EU 2014; L13: 1-73
• 14 Sgouros G, Bolch WE, Chiti A. et al. Dosimetry-Guided Radiopharmaceutical Therapy. Journal of the ICRU 2021; 21: 1-212
• 15 Hardiansyah D, Maass C, Attarwala AA. et al. The role of patient-based treatment planning in peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging 2016; 43: 871-880
• 16 Glatting G, Bardiès M, Lassmann M. Treatment planning in molecular radiotherapy. Zeitschrift fur Medizinische Physik 2013; 23: 262-269
• 17 Del Guerra A, Bardies M, Belcari N. et al. Curriculum for education and training of medical physicists in nuclear medicine: recommendations from the EANM Physics Committee, the EANM Dosimetry Committee and EFOMP. Physica medica: PM : an international journal devoted to the applications of physics to medicine and biology: official journal of the Italian Association of Biomedical Physics 2013; 29: 139-162
• 18 Marcu LG, Abbott NL, Appelt A. et al. The role of medical physicists in clinical trials across Europe. Phys Med 2022; 100: 31-38
• 19 Kletting P, Schimmel S, Hanscheid H. et al. The NUKDOS software for treatment planning in molecular radiotherapy. Z Med Phys 2015; 25: 264-274
• 20 Della Gala G, Bardiès M, Tipping J. et al. Overview of commercial treatment planning systems for targeted radionuclide therapy. Physica Medica 2021; 92: 52-61
• 21 Hänscheid H, Lapa C, Buck AK. et al. Dose Mapping After Endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a Single Measurement After 4 Days. J Nucl Med 2018; 59: 75-81
• 22 Maass C, Sachs JP, Hardiansyah D. et al. Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule. EJNMMI research 2016; 6: 30
• 23 Hänscheid H, Lassmann M. Will SPECT/CT Cameras soon be able to display Absorbed Doses? Dosimetry from Single Activity Concentration Measurements. J Nucl Med 2020; 61: 1028-1029
• 24 Gustafsson J, Taprogge J. Theoretical aspects on the use of single-time-point dosimetry for radionuclide therapy. Phys Med Biol 2022; 67
• 25 Kletting P, Glatting G. Pharmacokinetic Modelling in Nuclear Medicine. Der Nuklearmediziner 2018; 41: 52-60
• 26 Jiménez-Franco L, Kletting P, Glatting G. Möglichkeiten zur Verbesserung der Dosimetrie und Therapieplanung in der Molekularen Radiotherapie durch maschinelles Lernen. Der Nuklearmediziner 2019; 42: 148-156
• 27 Visvikis D, Lambin P, Beuschau Mauridsen K. et al. Application of artificial intelligence in nuclear medicine and molecular imaging: a review of current status and future perspectives for clinical translation. Eur J Nucl Med Mol Imaging 2022;
• 28 Hustinx R, Pruim J, Lassmann M. et al. An EANM position paper on the application of artificial intelligence in nuclear medicine. Eur J Nucl Med Mol Imaging 2022;
• 29 Aerts A, Eberlein U, Holm S. et al. EANM position paper on the role of radiobiology in nuclear medicine. Eur J Nucl Med Mol Imaging 2021; 48: 3365-3377
• 30 Lassmann M, Glatting G. Dosimetrie für die Nuklearmedizinische Therapie. Der Nuklearmediziner 2018; 41: 11-12
• 31 Lassmann M, Glatting G. Grundlagen der patientenspezifischen Dosimetrie bei Radionuklidtherapien. Der Nuklearmediziner 2008; 31: 93-100
• 32 Dale R, Carabe-Fernandez A. The radiobiology of conventional radiotherapy and its application to radionuclide therapy. Cancer Biother Radiopharm 2005; 20: 47-51
• 33 Del Prete M, Buteau FA, Arsenault F. et al. Personalized (177)Lu-octreotate peptide receptor radionuclide therapy of neuroendocrine tumours: initial results from the P-PRRT trial. Eur J Nucl Med Mol Imaging 2019; 46: 728-742